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Meta-Analysis of Multi-Arm Trials Using Empirical Logistic Transform
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Abstract: Meta-analysis of multi-arm trials has been used increasingly in recent years. The aim of meta-analysis
for multi-arm trials is to combine evidence from all possible similar studies. In this paper we propose normal
approximation models by using empirical logistic transform to compare different treatments in multi-arm trials,
allowing studies of both direct and indirect comparisons. Additionally a hierarchical structure is introduced in the
model to address the problem of heterogeneity among different studies. The proposed models are performed using
the data from 31 randomized clinical trials (RCTs) which determine the efficacy of antiplatelet therapy in maintaining
vascular patency.
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1 INTRODUCTION
Most meta-analysis has focused on summarising of treatment
effect measures based on comparisons of two treatments. Some
meta-analysis data sets contain information on more than two
treatments comparing evidence of multi-arm trials compar-
isons. This type of data is called Multi-arm trials in this pa-
per although some authors call it mixed treatment comparison
(MTC). Higgins and Whitehead [1] presented a random effect
meta-analysis for binary data and introduced an idea of ‘bor-
rowing strength’ from indirect comparison. They considered
using the general parameter approach and the exact binomial
approach to estimate parameters of interest in a meta-analysis.
Lu and Ades [2] proposed a Bayesian hierarchical model us-
ing the Markov Chain Monte Carlo to represent meta-analysis
of multi-arm trials. Inconsistency in multi-arm trials evidence
structure was examined by Lu and Ades [3]. They performed
a Bayesian hierarchical model with fixed effects or random ef-
fects for fitting multi-arm trials under the assumption that the
available evidence sources were consistent in estimating all
treatment contrasts.
In meta-analysis for comparing two treatments, we usually
collected all the studies providing information on comparing
those two treatments directly. However some studies in multi-
arm trials give a useful information on indirect comparison in
a situation where the treatments have not been directly com-
pared. Thus, there are two types of treatment comparisons
in a meta-analysis of multi-arm trials: one is to compare two
treatments directly, the other is to use information from indi-
rect comparisons. For example, from antiplatelet data given in
Table 2, there are three groups of studies available: treatments
A, B and C; the control group of the meta-analysis is treatment
C, studies in group GAB compare treatment A versus B, stud-
ies in group GBC compare treatment B versus C, and studies
in group GAC compare treatment A versus C and our aim is
to compare treatment A versus B. The studies in group GBC
and GAC then provide the indirect comparison for treatment A
versus B. Later in this paper, we will blur the concept between
direct and indirect comparisons since our model can actually
give estimate of the treatment effect between any two arms of
all treatments involved in the multi-arm trials.
The direct and indirect comparisons for RCTs in a meta-
analysis have been expressed by several authors [2–6]. In this
paper we propose a normal approximation model based on the
empirical logistic transform. There are at least two advantages
comparing to other methods: (1) the proposed empirical log-
odds ratio models exclude the trial effects and then it will give
an unbiased estimate for treatment effect while the other meth-
ods may give biased estimates in some circumstances (see for
example the discussion on page 59 in [7]); (2) The computation
is very efficient and fast. The method has been used for the sys-
tematic reviews of antiplatelet trialists’ collaboration [8] which
investigates the efficacy of antiplatelet therapy in maintaining
vascular patency in various categories of patients. The paper is
organized as follows. We begin by introducing the data struc-
ture of multi-arm trials and performing empirical log-odds and
empirical log-odds ratio models in Section 2.1. The maximum
likelihood method is illustrated in Section 2.2. The last section
concludes the ideas of this paper and gives some comments.
2 METHODOLOGY
In this section we shall propose our ideas of empirical log-odds
and empirical log-odds ratio models through the antiplatelet
data. Clinically after coronary artery revascularisation of pa-
tients, whether by coronary artery bypass grafting or by percu-
taneous transluminal coronary angioplasty, angiographic stud-
ies show substantial rates of reocclusion [9]. Experimental and
clinical evidence suggests that antiplatelet therapy may help
prevent vascular graft or arterial occlusions, particularly during
the period soon after vascular procedures, before any intimal
damage has healed [10, 11]. The data was analyzed in order
to determine the efficacy of antiplatelet therapy in maintain-
ing vascular patency. There are 31 RCTs in total investigating
the use of aspirin plus dipyridamole, or aspirin alone, in the
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comparison with the control group. The trials compare three
treatments A (aspirin plus dipyridamole), B (aspirin only) and
C (control group), where 6 trials (1-6) compare A, B and C, 4
trials (7-10) compare A and B, 13 trials (11-24) compare A and
C and 7 trials (25-31) compare B and C. The data is shown in
Table 2.
2.1 Models
For convenience, we partition the data set into four groups. Let
G1 = {1, . . . , 6}, G2 = {7, . . . , 10}, G3 = {11, . . . , 24} and
G4 = {25, . . . , 31} be four sets of studies comparing treatment
A versus B versus C, A versus B, A versus C and B versus
C, respectively. Let riA, riB and riC be the numbers of pa-
tients that have reocclusions on treatments A, B and C respec-
tively where the ith study is in G1 ∪ G2 ∪ G3, G1 ∪ G2 ∪ G4
and G1 ∪ G3 ∪ G4, respectively, where ‘∪’ stands for ‘and’.
The total numbers of patients are niA, niB and niC , respec-
tively. Let piiA, piiB and piiC be the probabilities of patients
that have reocclusions on treatments A, B and C respectively in
the ith study. The riA, riB and riC are thus binomially dis-
tributed as Bin(piiA, niA), Bin(piiB , niB) and Bin(piiC , niC)
respectively. Suppose that XiA, XiB and XiC are the em-
pirical logistic transforms, called the empirical log-odds for
(riA, niA), (riB , niB) and (riC , niC) respectively, where for
example the empirical logistic transform of XiA is defined by
log(riA + 0.5)/(niA − riA + 0.5) (we may also use notation
ln(·) here) where i is in the set G1 ∪ G2 ∪ G3. From Cox
and Snell [7, page 31], if riA is not too small or not too close
to niA, the empirical logistic transform XiA has an approx-
imation normal distribution with mean log(piiA/(1 − piiA)).
The variance can be estimated from the data: σ̂2iA = (niA +
1)/((riA + 0.5)(niA − riA + 0.5)). It is the same for XiB and
XiC . The models on the log-odds scale for each group are de-
fined as follows
i ∈ G1,
 XiC = αi + σiCiC ,XiA = αi + δi,AC + σiAiA,
XiB = αi + δi,BC + σiBiB ,
i ∈ G2,
{
XiB = αi + σiBiB ,
XiA = αi + δi,AB + σiAiA,
i ∈ G3,
{
XiC = αi + σiCiC ,
XiA = αi + δi,AC + σiAiA,
i ∈ G4,
{
XiC = αi + σiCiC ,
XiB = αi + δi,BC + σiBiB .
These models are called empirical log-odds models. The σ2iA,
σ2iB and σ2iC are the variances of empirical log-odds XiA, XiB
and XiC , respectively. The iA, iB and iC are independent
and follow the standard normal distribution and correspond
to the random sampling errors of the models XiA, XiB and
XiC within the ith study respectively. All random sampling
errors are therefore independent and normally distributed as
N(0, σ2iA), N(0, σ
2
iB) and N(0, σ2iC), respectively. The δi,AC ,
δi,BC and δi,AB are the treatment effects, which are defined,
for example
δi,AC = log
piiA
1− piiA − log
piiC
1− piiC .
It is called log-odds ratio between treatment A and treatment
C, measuring the effect of treatmentA comparing to the control
group C. This is the parameter of interest. The main purpose of
the meta-analysis is to find the overall estimates of the log-odds
ratios between treatmentsA versusC, B versusC andA versus
B. We may assume a fixed effect or a random effect. The fixed
effect model assumes that all the δi,AC’s are the same as δAC ,
where δAC is a fixed treatment effect between the treatment A
and the control group C for all studies in G1 and G3. The fixed
treatment effect δBC can be considered in the same way. It
is important to note that the treatment effect δi,AB or its fixed
effect δAB is not a free parameter since δAB = δAC − δBC .
To address the problem of between-study heterogeneity, we
usually use a random effect model, i.e. assume δi,AC , δi,BC
and δi,AB are random variables. If we use a normal distri-
bution, the random effect model is to assume that the treat-
ment effects δi,AC , δi,BC and δi,AB are normally distributed as
N(µAC , τ2AC), N(µBC , τ
2
BC) and N(µAC − µBC , τ2AB), re-
spectively. For the studies involved in G1, the treatment effects
δi,AC and δi,BC are defined based on the same baseline treat-
ment C and therefore may be dependent. Let ρ be the correla-
tion coefficient between the treatment effects δi,AC and δi,BC ,
we may define a model as
(
δi,AC
δi,BC
)
∼ N
((
µAC
µBC
)
,
(
τ2AC ρτACτBC
ρτACτBC τ
2
BC
))
.
(1)
The parameters µAC and µBC are the overall mean effects be-
tween the control group C and the treatment A, and the control
group C and the treatment B, respectively. The τ2AC and τ2BC
measure the between-study heterogeneity of the treatment ef-
fects δi,AC and δi,BC , respectively. The correlation coefficient
ρ measures the amount of linear association between δi,AC and
δi,BC . In group G2, treatments A and B are involved. From
(1), we have
δi,AB = δi,AC − δi,BC ∼ N(µAC − µBC , τ2AB), (2)
where τ2AB = τ2AC+τ2BC−2ρτACτBC . The entries on the diag-
onal of the covariance matrix in (1) are often called the hetero-
geneity parameters of the treatment effects in a meta-analysis.
The useful property of the model parameterisation is the corre-
lation structure of the covariance matrix. An important special
case is that the heterogeneity parameters of the treatment ef-
fects are assumed to be the same, i.e. τAC = τBC = τAB ,
called homogeneity of variances. Hence the correlation coeffi-
cient ρ takes the value 1/2 because the treatment effects δi,AC
and δi,BC involve the control group C in the same way. A gen-
eral model is to allow the heterogeneity parameters of the treat-
ment effects to be different for each treatment effect related to
the control group, called heterogeneity of variances. The co-
variance matrix will be in the standard form as shown in (1)
and (2).
The αi in each group is the trial effect. We can consider the
following two assumptions. The first one is that the trial effects
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are assumed to be study-level effects, which means the αis are
different fixed parameters. We need to include 31 different un-
known parameters in the model. The second one is that we
may assume a model for αi’s. A special case is to assume that
all trial effects are the same: α = α1 = α2 = . . . = α31.
Conversely if the trial effect is assumed to be a random effect,
we may assume that αi ∼ N(µα, τ2α) where µα is the over-
all mean of the trial effects and τα measures the magnitude of
the variation between the studies. The standard random effect
model used in meta-analysis was described by [12]. To capture
skewness and heavy tails in the distribution of the trial effect,
we may use a mixture of normal distributions [13]. However,
in practice the trial effects in most meta-analysis would not sat-
isfy any model since different experiment designs and different
data analysis models are used in different studies. Most of the
existed methods therefore used the first assumption. Note that
the number of unknown parameters is the same as the number
of studies. This will result in some theoretical and computa-
tional problems. The accuracy of the estimation depends on
the sample size of each study not the overall sample size of the
pool in the meta-analysis. The estimates of some parameters
may not be consistent. Due to the large number of parameters,
the computation is usually unstable. We therefore propose the
following empirical log-odds ratio model. Based on the em-
pirical log-odds models, a model on the log-odds ratio scale is
suggested here. Let Yi,AC = XiA−XiC , Yi,BC = XiB−XiC
and Yi,AB = XiA − XiB , which are called as the empirical
log-odds ratio for XiA versus XiC , XiB versus XiC , and XiA
versus XiB , respectively. The models on the log-odds ratio
scale in each group can be defined as follows
i ∈ G1,
{
Yi,AC = δi,AC + σi,ACi,AC ,
Yi,BC = δi,BC + σi,BCi,BC ,
(3)
i ∈ G2, Yi,AB = δi,AB + σi,ABi,AB , (4)
i ∈ G3, Yi,AC = δi,AC + σi,ACi,AC , (5)
i ∈ G4, Yi,BC = δi,BC + σi,BCi,BC . (6)
The above models are called empirical log-odds ratio models.
The trial effects αi’s are no longer in the above models. Note
that the models Yi,AC and Yi,BC for the studies in G1 are not
independent. The treatment effects δi,AC and δi,BC are jointly
normally distributed as shown in (1). The σ2i,AC , σ2i,BC and
σ2i,AB are variances of the log-odds ratios Yi,AC , Yi,BC and
Yi,AB respectively, which can be calculated from σ2iA, σ2iB and
σ2iC by for example σ2i,AC = σ2iA + σ2iC . Consequently the
empirical log-odds ratio (Yi,AC , Yi,BC)t for studies in G1 is
distributed as
N
((
µAC
µBC
)
,
(
τ2AC + σ
2
i,AC ρτACτBC + σ
2
iC
ρτACτBC + σ
2
iC τ
2
BC + σ
2
i,BC
))
.
(7)
The µAC and µBC are the overall mean effects for the mod-
els Yi,AC and Yi,BC . The variances of the models Yi,AC and
Yi,BC are τ
2
AC + σ
2
i,AC and τ2BC + σ2i,BC respectively. The
covariance between both models is ρτACτBC + σ2iC . Addi-
tionally the empirical log-odds ratio models for G2, G3 and
G4 are normally distributed as N(µAC − µBC , τ2AB + σ2i,AB),
N(µAC , τ2AC+σ
2
i,AC) andN(µBC , τ2BC+σ2i,BC), respectively.
2.2 Estimation
To make inference, the maximum likelihood method is applied
to estimate the unknown parameters in the empirical log-odds
ratio models given in (3) - (6). Our aim is to estimate the un-
known parameters for the meta-analysis consisting of 31 stud-
ies. Let θ be the collection of all unknown parameters for the
meta-analysis. Suppose that θ can take any value within ad-
missible ranges Θ. The method of maximum likelihood is to
find the value θ̂ within Θ which makes the likelihood function
of θ as large as possible. The log-likelihood function for the
empirical log-odds ratio models (3) to (6) can be written as
l(θ) =
∑
i∈G1
log p(Yi,AC , Yi,BC |θ) +
∑
i∈G2
log p(Yi,AB |θ)
+
∑
i∈G3
log p(Yi,AC |θ) +
∑
i∈G4
log p(Yi,BC |θ).
Notice that the l(θ) is a summation of log-likelihoods from G1
to G4. The p(Yi,AC , Yi,BC |θi), p(Yi,AB |θi), p(Yi,AC |θi) and
p(Yi,BC |θi) represent the joint probabilities of the observing
data that has been collected in G1, G2, G3 and G4 respectively.
Maximizing the log-likelihood function, we use the function
nlme in the software R to solve the unknown parameters. As
described in the previous section, there are two assumptions
of heterogeneity parameters: homogeneity and heterogeneity
variances. For the model with homogeneity variances (Model
1 in Table 1), we assume that τAC = τBC = τAB = τ and
the correlation coefficient between the treatment effects takes
1/2. For the model with heterogeneity variances (Model 2 in
Table 1), the correlation coefficient is an unknown parameters.
Thus the θ in Model 1 is
{
µAC , µBC , τ
2
}
while θ in Model 2
is
{
µAC , µBC , τ
2
AC , τ
2
BC , ρ
}
and τ2AB is given in (2).
2.3 Numerical results
The estimates of unknown parameters in Model 1 and Model
2 are shown in Table 1. From Model 1, the overall means of
treatment effects A versus B, A versus C and B versus C are
0.108146, -0.568930 and -0.677076 respectively and the vari-
ations between studies in those comparisons are assumed the
same, 0.275320. The overall means estimated from Model 2
are quite similar. Those means for Model 2 are 0.064521, -
0.599244 and -0.663766, and the variations between studies are
0.093380, 0.33440 and 0.318274 respectively. The correlation
coefficient in Model 2 is 0.96. Notice that the estimator of ρ is
quite close to one and τAB is very small. All treatment effects
are on the log-odds ratio scale. In term of interpretation, we
consider the overall means on the odds ratio (OR) scale. The
results obtained from both models are quite close. They indi-
cate that both treatment A and treatment B reduce the rates of
reocclusion significantly by about 40% comparing to control
group. However, the difference between treatment A and treat-
ment B is neglect although treatment B is even slightly better
than treatment A (improved by about 11% using Model 1 and
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Table 1: Results for the empirical log-odds ratio models
Model δAB δAC δBC
µAB τAB µAC τAC µBC τBC
Model 1 0.108146 0.275320 -0.568930 0.275320 -0.677076 0.275320
(SD) (0.156391) (0.136747) (0.161554) (0.136747) (0.150660) (0.136747)
OR scale 1.114210 0.566130 0.508100
Model 2 0.064521 0.093380 -0.599244 0.333440 -0.663766 0.318274
(SD) (0.053287) (0.065361) (0.171172) (0.228035) (0.187616) (0.204939)
OR scale 1.066648 0.549226 0.5149085
Model 3 0.062605 0.00000009 -0.590714 0.335648 -0.653320 0.212374
(SD) (0.252691) (0.324800) (0.262792) (0.502075) (0.241205) (0.218013)
OR scale 1.064607 0.553931 0.520315
6% using Model 2). In both models, we used empirical log-
odds ratio models to eliminate the nuisance parameters (trial
effects). The computation is very efficient and very stable, it
converges very fast for almost any starting points.
3 CONCLUSION
We demonstrated a normal approximation model based on em-
pirical logistic transform to multi-arm trials data. The approx-
imation is usually quite good if the number of observations in
each study is not too small (the number of samples in a single
study should usually be larger than 20). Since the normal distri-
bution is used, the calculation from the normal approximation
is much faster than from the model with exact binomial distri-
butions. It takes just about 2 seconds using Model 1 for the
example discussed in this paper, but it takes about 30 minutes
if we use the exact binomial distributions and conditional like-
lihood approach (it takes about 5 minutes if an unconditional
likelihood approach is used, but this method needs to estimate
αs’s). The final results from both models are very close.
The estimation of ρ is quite trick. In our example, the in-
formation for ρ or τAB mainly comes from G2. Due to small
number of studies involved in G2, we should be careful to ex-
plain the values of the estimates, which ρ is quite close to 1
and τ is quite close to zero. In this case, a way is to assume
the between-study heterogeneity (τ2AB) of indirect comparison
was not relatively estimated from the between-study hetero-
geneities (τ2AC or τ2BC) of the direct comparison. This is the
Model 3 given in Table 1, which τAB is an independent un-
known parameter and ρ is assumed as 1/2. The results from
Models 2 and 3 are almost the same. Several authors ([4], [6])
pointed out in the same way. Whenever there is no or insuf-
ficient evidence on direct comparison from RCTs, the indirect
comparison may provide useful or supplementary information
on the treatment effect. However the validity of the indirect
comparisons depends on the internal validity and similarity of
the included studies (see [6]). If the trial effects in the empirical
log-odds model are assumed to be study-level fixed effects, the
estimation is not simple as many parameters are involved in the
model. This leaded to a problem of inconsistent estimate. Solv-
ing the problem of the trial effect, the empirical log-odds ratio
model was suggested in order to eliminate the trial effects from
the model. Some other methods can also be used to address
the problem, for example, a conditional approach based on the
binomial distribution. We will not discuss the details here.
ATC Collaboration [8] concluded that antiplatelet therapy
(aspirin plus dipyridamole (A) or aspirin alone (B)) produced a
highly significant (2p ≤ 0.00001) reduction in vascular occlu-
sion in a wide range of patients. The odds of vascular graft or
arterial occlusion were reduced by about 40% while treatment
continued. Our numerical results in the previous section are
similar to the conclusion from [8].
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